← Ablatotech Vitals
InfectiousDisease EvidenceDigest

Clinical management of infections in patients receiving emerging anti-PD-1/PD-L1 immune checkpoint inhibitor therapies

InfectiousDisease · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
November 20, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Patients receiving anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) for cancer treatment face a distinct infectious risk profile due to immune modulation. Emerging evidence highlights the importance of vigilant infection monitoring and tailored antimicrobial strategies in this population. Cutaneous immune-related adverse events such as rash may correlate with treatment response but also complicate infection risk assessment. Clinicians should balance immunotherapy benefits with infection prevention and management, recognizing that data on optimal infectious disease care in this setting remain limited and evolving.

Clinical bottom line

Patients receiving anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) for cancer treatment face a distinct infectious risk profile due to immune modulation. Emerging evidence highlights the importance of vigilant infection monitoring and tailored antimicrobial strategies in this population. Cutaneous immune-related adverse events such as rash may correlate with treatment response but also complicate infection risk assessment. Clinicians should balance immunotherapy benefits with infection prevention and management, recognizing that data on optimal infectious disease care in this setting remain limited and evolving.

What the evidence shows

Anti-PD-1/PD-L1 ICIs have transformed oncology by enhancing antitumor immunity, particularly in non-small cell lung cancer (NSCLC), renal cell carcinoma, and triple-negative breast cancer (Bullock et al., 2024; Grimm et al., 2020). These agents block inhibitory signals on T cells, restoring immune activity against tumors but also altering host defense mechanisms.

Yang et al. (2024) reported that rash development during PD-1/PD-L1 therapy in NSCLC patients may serve as a clinical biomarker of immune activation and improved oncologic outcomes. However, such cutaneous manifestations can mimic or mask infectious processes, complicating clinical evaluation. Logan et al. (2023) described rare but severe acral necrosis following PD-L1 blockade, underscoring the potential for immune-mediated tissue damage that may predispose to secondary infections.

The immunomodulatory effects of PD-1/PD-L1 inhibitors may increase susceptibility to opportunistic infections, although large-scale epidemiologic data remain sparse. The immune checkpoint blockade can disrupt immune homeostasis, potentially impairing pathogen clearance or triggering immune reconstitution inflammatory syndrome-like phenomena. Current clinical experience suggests heightened vigilance for bacterial, viral, and fungal infections is warranted, especially in patients with additional immunosuppressive factors or combination therapies (Cole et al., 2014).

Preclinical and translational research efforts are ongoing to optimize PD-1/PD-L1 targeting and mitigate adverse effects, including infectious complications (Bullock et al., 2024; Grimm et al., 2020). Novel approaches such as combining checkpoint inhibitors with photodynamic ablation or targeting alternative immune checkpoints may influence infectious risk profiles in the future (Bullock et al., 2024; unreferenced preclinical data).

Caveats and uncertainty

The current evidence base is limited by small cohort sizes, retrospective designs, and heterogeneous cancer populations. Most studies focus on oncologic efficacy and immune-related adverse events rather than systematic infectious disease outcomes. There is a lack of randomized controlled trials specifically addressing infection prevention or management in patients on anti-PD-1/PD-L1 therapy.

The interplay between immune checkpoint inhibition and infection susceptibility is complex and incompletely understood. Immune activation may paradoxically reduce some infection risks while increasing others. The role of concomitant immunosuppressive treatments, prior therapies, and patient comorbidities further complicates risk stratification.

Cutaneous adverse events such as rash and necrosis may be immune-mediated or infectious, requiring careful diagnostic evaluation. There are no standardized guidelines for antimicrobial prophylaxis or empiric therapy tailored to this population. Clinicians must individualize decisions based on clinical context and emerging evidence.

How this may change practice

Clinicians managing patients on anti-PD-1/PD-L1 ICIs should maintain a high index of suspicion for infections, particularly when immune-related adverse events overlap with infectious symptoms. Early dermatologic consultation and microbiologic evaluation are advisable for cutaneous manifestations.

Routine infectious disease screening and prophylaxis are not yet standardized but may be considered in high-risk patients, such as those receiving combination immunosuppressive regimens or with prior opportunistic infections. Multidisciplinary collaboration between oncology, infectious diseases, and dermatology can optimize outcomes.

Ongoing research and real-world data collection are critical to define evidence-based infection management protocols. Awareness of emerging therapies and their infectious implications will inform future clinical guidelines and improve patient safety.


References

  1. Yang Yongsheng, et al. Impact of Rash Development for Patients with Non-Small Cell Lung Cancer Receiving PD-1/PD-L1-Based Immune Checkpoint Inhibitor Therapy. Lung Cancer. 2024. DOI:10.1183/13993003.congress-2024.pa4219
  2. Bullock Kennady K., et al. Beyond Anti-PD-1/PD-L1: Improving Immune Checkpoint Inhibitor Responses in Triple-Negative Breast Cancer. Cancers. 2024.
  3. Grimm Marc-Oliver, et al. New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies. Journal of Clinical Medicine. 2020;9:2056. DOI:10.3390/jcm9020565
  4. Cole, P., et al. Durvalumab. Human anti-PD-L1 monoclonal antibody, Immune checkpoint inhibitor, Oncolytic. Drugs of the Future. 2014.
  5. Logan Sam, et al. Acral Necrosis After PD-L1 Immune Checkpoint Inhibitor Therapy. Cutis. 2023;111:77-80. DOI:10.12788/cutis.0777

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team